P2RY12 and COVID-19: In the antiplatelet domain of the REMAP-CAP trial, randomization to an antiplatelet agent (ASA or P2Y12) while concurrently receiving therapeutic-dose heparin (n = 122 critically ill patients with COVID-19) did not improve OSFD (OR, 0.73; 95% CrI, 0.44-1.21) or survival to hospital discharge (OR, 0.72; 95% CrI, 0.41-1.28) compared with low-dose thromboprophylaxis and no antiplatelet [18].